Haritoglou Ingrid, Wolf Armin, Maier Tanja, Haritoglou Christos, Hein Rüdiger, Schaller Ulrich Christoph
Department of Ophthalmology, Ludwig Maximilians University, Munich, Germany.
Ophthalmologica. 2009;223(4):239-43. doi: 10.1159/000206139. Epub 2009 Mar 6.
Evaluation of the protein osteopontin (OPN) as a potential new marker in comparison to melanoma inhibitory activity (MIA) for screening and detection of metastatic uveal melanoma.
Plasma levels of 32 patients with uveal melanoma were analyzed for OPN and MIA by enzyme-linked immunosorbent assay (ELISA). Fourteen of these patients had clinically detectable liver metastases.
Median plasma concentration of OPN in patients with metastatic disease was 152.01 ng/ml compared to 47.39 ng/ml in patients without clinically detectable metastases (p < 0.001). The difference between the median MIA plasma levels in patients with (13.11 ng/ml) and patients without (5.64 ng/ml) metastatic disease was also statistically significant (p < 0.001). No correlation could be found between MIA or OPN levels and tumor height in patients without clinically detectable metastases.
The proteins MIA and OPN seem to be promising tumor markers for the metastasis screening in patients with uveal melanoma.
与黑色素瘤抑制活性（MIA）相比，评估骨桥蛋白（OPN）作为转移性葡萄膜黑色素瘤筛查和检测的潜在新标志物。
采用酶联免疫吸附测定（ELISA）分析32例葡萄膜黑色素瘤患者血浆中OPN和MIA的水平。其中14例患者有临床可检测到的肝转移。
有转移性疾病患者的OPN血浆中位浓度为152.01 ng/ml，而无临床可检测到转移的患者为47.39 ng/ml（p<0.001）。有转移性疾病患者（13.11 ng/ml）和无转移性疾病患者（5.64 ng/ml）的MIA血浆中位水平差异也具有统计学意义（p<0.001）。在无临床可检测到转移的患者中，未发现MIA或OPN水平与肿瘤高度之间存在相关性。
MIA和OPN蛋白似乎是葡萄膜黑色素瘤患者转移筛查中有前景的肿瘤标志物。
